These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 226672)

  • 1. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
    Hidaka H; Hayashi H; Kohri H; Kimura Y; Hosokawa T; Igawa T; Saitoh Y
    J Pharmacol Exp Ther; 1979 Oct; 211(1):26-30. PubMed ID: 226672
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of platelet cyclic 3',5'-adenosine-monophosphate phosphodiesterases by pentifylline.
    Stefanovich V
    Arzneimittelforschung; 1975 May; 25(5):740-1. PubMed ID: 170944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
    Nemoz G; Prigent AF
    Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
    [No Abstract]   [Full Text] [Related]  

  • 4. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent--II. Inhibition of platelet phosphodiesterase.
    Mikashima H; Nakao T; Goto K; Ochi H; Yasuda H; Tsumagari T
    Thromb Res; 1984 Sep; 35(5):589-94. PubMed ID: 6091293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.
    Ruppert D; Weithmann KU
    Life Sci; 1982 Nov; 31(19):2037-43. PubMed ID: 6294426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mepacrine-induced elevation of cyclic GMP levels and acceleration of reversal of ADP-induced aggregation in washed rabbit platelets.
    Matsuoka I; Suzuki T
    J Cyclic Nucleotide Protein Phosphor Res; 1983; 9(4-5):341-53. PubMed ID: 6147364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
    Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
    Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation.
    Hagiwara M; Endo T; Kanayama T; Hidaka H
    J Pharmacol Exp Ther; 1984 Feb; 228(2):467-71. PubMed ID: 6141286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human platelet cyclic AMP phosphodiesterase and of platelet aggregation by a hemisynthetic flavonoid, amentoflavone hexaacetate.
    Beretz A; Briançon-Scheid F; Stierlé A; Corre G; Anton R; Cazenave JP
    Biochem Pharmacol; 1986 Jan; 35(2):257-62. PubMed ID: 3002388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of adenosine on levels of adenosine cyclic 3',5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation.
    Haslam RJ; Rosson GM
    Mol Pharmacol; 1975 Sep; 11(5):528-44. PubMed ID: 170501
    [No Abstract]   [Full Text] [Related]  

  • 11. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
    Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
    J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits.
    Holbrook M; Coker SJ
    Br J Pharmacol; 1991 Aug; 103(4):1973-9. PubMed ID: 1655149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography.
    Umekawa H; Tanaka T; Kimura Y; Hidaka H
    Biochem Pharmacol; 1984 Nov; 33(21):3339-44. PubMed ID: 6093810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic nucleotide phosphodiesterase activity and the platelet release reaction.
    Taylor PM; Heptinstall S
    Thromb Haemost; 1978 Apr; 39(2):550-1. PubMed ID: 27878
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulation of cyclic AMP metabolism in human platelets. Sequential activation of adenylate cyclase and cyclic AMP phosphodiesterase by prostaglandins.
    Alvarez R; Taylor A; Fazzari JJ; Jacobs JR
    Mol Pharmacol; 1981 Sep; 20(2):302-9. PubMed ID: 6272089
    [No Abstract]   [Full Text] [Related]  

  • 16. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors.
    Ashida S; Sakuma K
    Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259
    [No Abstract]   [Full Text] [Related]  

  • 17. Selective phosphodiesterase inhibition and alterations of cardiac function by alkylated xanthines.
    Mushlin P; Boerth RC; Wells JN
    Mol Pharmacol; 1981 Jul; 20(1):179-89. PubMed ID: 6270531
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of platelet aggregation and stimulation of guanylate cyclase by an antianginal agent molsidomine and its metabolites.
    Nishikawa M; Kanamori M; Hidaka H
    J Pharmacol Exp Ther; 1982 Jan; 220(1):183-90. PubMed ID: 6118429
    [No Abstract]   [Full Text] [Related]  

  • 19. Imidazoquinoline derivatives: potent inhibitors of platelet cAMP phosphodiesterase which elevate cAMP levels and activate protein kinase in platelets.
    Seiler S; Gillespie E; Arnold AJ; Brassard CL; Meanwell NA; Fleming JS
    Thromb Res; 1991 Apr; 62(1-2):31-42. PubMed ID: 1649498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet effects of KW-7, a new inhibitor of cyclic nucleotide phosphodiesterases.
    Wu CC; Wang WY; Kuo RY; Chang FR; Wu YC
    Eur J Pharmacol; 2004 Jan; 483(2-3):187-94. PubMed ID: 14729106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.